about
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.Phase-II trials in osteosarcoma recurrences: A systematic review of past experience.Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).A positioning pillow to improve lumbar puncture success rate in paediatric haematology-oncology patients: a randomized controlled trial.Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's)Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases.The off-label use of targeted therapies in sarcomas: the OUTC'S programEwing sarcoma: the pediatrician's point of view.Desmoplastic small round cell tumor: current management and recent findings.Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial.Thymus and mediastinal node involvement in childhood Langerhans cell histiocytosis: long-term follow-up from the French national cohort2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer.High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group.Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.Management of Febrile Neutropenias in Adolescents and Young Adults: A Cost-Minimization Analysis Between Adult Versus Pediatric Units.A Review of Health Behaviors in Childhood and Adolescent Cancer Survivors: Toward Prevention of Second Primary Cancer.Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.[Prognostic factors for febrile neutropenia].Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group.[Management of febrile neutropenias in adolescents and young adults: Differences of practice between adult and pediatric units].Cabergoline therapy of paraneoplastic Cushing syndrome in children.Critical Review of Clinical Practice Guidelines for Fertility Preservation in Teenagers and Young Adults with Cancer.18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization.[Pain and cancer Information dedicated to cancer patients and relatives].
P50
Q27851824-BE0DE60C-6CA5-4BB5-89AF-D5E4ED7064A6Q30235839-E6E0F99B-39FE-413A-AF62-7CCAB1317345Q31018689-F65DF05E-6A75-4A26-A44F-C57E82856DB1Q33400103-163C9B14-E564-451F-AC34-369E01B3E33BQ33416199-28BB6545-886E-4D23-A85D-8F5EB533EFC8Q33654843-553EBA6F-7BBD-46F7-8896-38463E24337AQ33805555-0C05E53E-0F3D-43C8-AE8B-450E70F3342FQ34028842-749B54B4-1FC7-46F8-AE56-FE134DFF68BFQ34897996-54FADA99-37C5-436A-8029-235E7582C2BBQ35719677-888C75AA-A48E-400B-AC29-67C85819F620Q35898508-DD7A68F5-3097-4AE1-A0BE-9638CEFD5D76Q37151999-4381B0EE-6BAD-489D-9A4A-7B81757F9C0EQ37298083-9BF4927C-6482-482A-AC14-67E7FAAB0121Q37396977-8B08E624-1FB5-49A7-8B5F-E7C5A40BB322Q37615003-3BBC0727-B0C1-40CE-A8E1-C5AFB5AFFEADQ38573422-AB526808-9648-42B5-B0D9-C02C09F3C5F9Q38693245-C4EEAE85-7665-42E9-BC68-911E99D7DEEAQ38712191-E46FE659-7CC7-4091-9B4E-D311E3B27E39Q38870980-821A5E2D-C876-427E-9030-92B47C8FA2F0Q40476661-8E4B6671-D958-4F31-9C3C-B23F1F090C94Q40755680-822764E4-FF9D-4E7A-82D5-17D7EEC28B89Q40992454-10372D67-C2B5-42D8-A61C-69CDFEBE49CFQ42958207-DE345778-8304-40B1-9747-854CADA95F5AQ43070482-B37074AF-8612-49C1-A5E2-4DD67DA28A9BQ43290076-589C198F-1B85-484E-9A41-BA4A10318108Q45176482-30209ACB-6ABC-4FC6-9A49-F5D38ADDEC76Q46582703-F52BB84C-0642-41E7-940C-0A06EAA1B319
P50
name
Perrine Marec-Bérard
@ast
Perrine Marec-Bérard
@en
Perrine Marec-Bérard
@nl
type
label
Perrine Marec-Bérard
@ast
Perrine Marec-Bérard
@en
Perrine Marec-Bérard
@nl
altLabel
Perrine Marec-Berard
@en
prefLabel
Perrine Marec-Bérard
@ast
Perrine Marec-Bérard
@en
Perrine Marec-Bérard
@nl